These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19472394)

  • 1. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.
    Adams SF; Levine DA; Cadungog MG; Hammond R; Facciabene A; Olvera N; Rubin SC; Boyd J; Gimotty PA; Coukos G
    Cancer; 2009 Jul; 115(13):2891-902. PubMed ID: 19472394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
    Bachmayr-Heyda A; Aust S; Heinze G; Polterauer S; Grimm C; Braicu EI; Sehouli J; Lambrechts S; Vergote I; Mahner S; Pils D; Schuster E; Thalhammer T; Horvat R; Denkert C; Zeillinger R; Castillo-Tong DC
    BMC Cancer; 2013 Sep; 13():422. PubMed ID: 24044611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
    Clarke B; Tinker AV; Lee CH; Subramanian S; van de Rijn M; Turbin D; Kalloger S; Han G; Ceballos K; Cadungog MG; Huntsman DG; Coukos G; Gilks CB
    Mod Pathol; 2009 Mar; 22(3):393-402. PubMed ID: 19060844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
    Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
    Leffers N; Gooden MJ; de Jong RA; Hoogeboom BN; ten Hoor KA; Hollema H; Boezen HM; van der Zee AG; Daemen T; Nijman HW
    Cancer Immunol Immunother; 2009 Mar; 58(3):449-59. PubMed ID: 18791714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Sato E; Olson SH; Ahn J; Bundy B; Nishikawa H; Qian F; Jungbluth AA; Frosina D; Gnjatic S; Ambrosone C; Kepner J; Odunsi T; Ritter G; Lele S; Chen YT; Ohtani H; Old LJ; Odunsi K
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18538-43. PubMed ID: 16344461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
    Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
    Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes.
    Stumpf M; Hasenburg A; Riener MO; Jütting U; Wang C; Shen Y; Orlowska-Volk M; Fisch P; Wang Z; Gitsch G; Werner M; Lassmann S
    Br J Cancer; 2009 Nov; 101(9):1513-21. PubMed ID: 19861998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
    Callahan MJ; Nagymanyoki Z; Bonome T; Johnson ME; Litkouhi B; Sullivan EH; Hirsch MS; Matulonis UA; Liu J; Birrer MJ; Berkowitz RS; Mok SC
    Clin Cancer Res; 2008 Dec; 14(23):7667-73. PubMed ID: 19047092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
    van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
    Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
    De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
    Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
    Hagemann AR; Hagemann IS; Cadungog M; Hwang WT; Patel P; Lal P; Hammond R; Gimotty PA; Chu CS; Rubin SC; Birrer MJ; Powell DJ; Feldman MD; Coukos G
    Cancer Biol Ther; 2011 Aug; 12(4):367-77. PubMed ID: 21785280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
    Tubridy EA; Eiva MA; Liu F; Omran DK; Gysler S; Brown EG; Roy AG; Zeng Y; Oh J; Cao Q; Gitto SB; Powell DJ
    Gynecol Oncol; 2024 May; 184():74-82. PubMed ID: 38290413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma.
    Raspollini MR; Castiglione F; Rossi Degl'innocenti D; Amunni G; Villanucci A; Garbini F; Baroni G; Taddei GL
    Ann Oncol; 2005 Apr; 16(4):590-6. PubMed ID: 15699022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
    Jäntti T; Luhtala S; Mäenpää J; Staff S
    Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.